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in 83% of the cases followed by transapical approach (10%). Most
procedures were performed in a catheterization laboratory (74%) or
hybrid room (29%). An anesthesiologist assisted the transfemoral/
subclavian approach procedures in 94% of centers. General anesthesia
was used systematically in 43% of the centers, and 34% used general
anesthesia occasionally (<25% of patients). TEE guidance was sys-
tematically used in 45% of centers. Valve type was spited half-half
between balloon-expandable (Edwards valve) and self-expandable
(mainly CoreValve) systems. Aortography was the most common
exam used for assessing residual aortic regurgitation (90%), followed
by hemodynamic evaluation (65%) and TEE (55%). Conversely, the
operators relied ﬁrsts on TEE (40%) in case of discrepancies, followed
by aortography (28%) and hemodynamic assessment (21%). Heparin
(99.4%) was the most common anticoagulation therapy during the
procedure, but activated clotting time (ACT) guidance was imple-
mented in only 36% of the centers.
CONCLUSIONS This survey highlights several differences in proce-
dural management particularly among the choice of the primary
anesthetic regimen and the systematic TEE support during TAVI.
Notably, discordance is present regarding the best technique to
evaluate AR after TAVI, one of the most important predictors of long-
term mortality.
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BACKGROUND Redo surgery for degeneration of biological aortic
valve prostheses can be a high-risk procedure. Transcatheter aortic
valve-in-valve implantation poses a less-invasive treatment alterna-
tive for these patients. We aim to present our clinical outcomes of
consecutive patients after a valve-in-valve TAVI (TAV-in-SAV) as
compared to a standard reoperation (SAV-in-SAV) for a failing surgical
bioprosthesis in a single center setting.
METHODS All SAV-in-SAV and TAV-in-SAV patients from January
2001 to October 2014 were retrospectively reviewed. Patients with
previous mechanical or transcatheter valves, active endocarditis and
concomitant cardiac procedures were excluded. Patient characteris-
tics, preoperative data, post-procedural complications and 30-day
mortality were collected from a designated database.
RESULTS Of all reviewed patients, 102 fulﬁlled the inclusion criteria: 50
(49%) underwent a transcatheter valve-in-valve procedure, while 52
(51%) patients underwent redo-surgery. TAV-in-SAV patients were
signiﬁcantly older and had a higher mean logistic EuroSCORE than pa-
tients in the SAV-in-SAV group (78.16.7years vs. 66.213.1years,
P<0.001 and 27.4%18.7% vs. 14.4%10%, P<0.001, respectively). There
was no signiﬁcant difference between the TAV-in-SAV and SAV-in-SAV
group in 30-day mortality (4% vs. 0%; P¼ 0.238), postoperative
myocardial infarction (2% vs. 2%; p¼0.49), stroke (4% vs. 2%; p¼0.614) or
dialysis (12% vs. 2%; p¼0.057). Postoperative pacemaker implantation
and chest tube output were higher in the SAV-in-SAV group compared to
the TAV-in-SAV group (21% vs. 6%, P¼0.042 and 0.91.0l vs. 0.60.9l,
P¼0.047, respectively). Postoperative gradients were signiﬁcantly higher
in the TAV-in-SAV group (18.68.7mmHG vs. 13.85.4mmHg; p¼0.008).
CONCLUSIONS Our study shows, irrespective of different baseline
comorbidities, a low 30-day mortality as well as low postoperative
myocardial infarction and stroke rates in patients with failed aortic bio-
prostheses treated either by surgical redo or transcatheter intervention.
The rate of dialysis in the TAV-in-SAV group as well as the high post-
operative pacemaker rate in the SAV-in-SAV group will require further
evaluation. Nonetheless, older patients or patientswith a high surgical risk
may beneﬁt from the transcatheter valve-in-valve procedure.
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BACKGROUND Subclinical cerebral ischemic lesions are detected by
diffusion- weighted magnetic resonance imaging (DW-MRI) in the
majority of patients after TAVR which may be associated with
impaired short term neurological outcome. The impact of the TAVR
device on cerebral ischemic lesions is not well deﬁned. We aimed to
analyze the incidence of cerebral ischemic lesions in a large cohort of
patients undergoing TAVR with different devices.
METHODS Consecutive high surgical risk patients with severe aortic
valve stenosis treated with TAVR underwent DW-MRI 2-4 days after
the procedure. DW-MRI scans were analyzed for the occurrence,
number and volume of new ischemic lesions by a blinded physician.
RESULTS One-hundred- ﬁfty-two patients were enrolled, the major-
ity received an Edwards SAPIEN 3 (ES 3) (57%), 15.2% an Edwards
SAPIEN XT (ES XT), 23.2% a Direct Flow Medical (DFM), 3.3% a Lotus
and 1.3% an Evolut R aortic valve. Cerebral ischemic lesions were
detected in 70.4%. None of the patients was neurologically symp-
tomatic. Cerebral lesions after TAVR were found for ES XT in 56.5%,
ES 3 in 70.9%, DFM in 85.7%, Lotus in 20% and Evolute R 100% of
patients, respectively, which was statistically signiﬁcant in univariate
analysis. Logistic regression analysis revealed valve type as the only
independent predictor for new cerebral ischemic lesions (p¼0.017).
CONCLUSIONS Asymptomatic cerebral ischemic lesions after TAVR
are observed frequently. The TAVR device type has a signiﬁcant
impact on the incidence of new cerebral ischemic lesions.
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BACKGROUND Registries for transcatheter valve-in-valve procedures
show peri procedural stroke rates of about 2%. Cerebral protection devices
may reduce the stroke rate and histopathology ﬁndings are unknown.
METHODS Twenty-one patients were treated with implantation of
TAVR prostheses into degenerated bioprotheses in the aortic (n¼16)
and mitral position (n¼5), combined with a Claret Cerebral Protection
System (Claret Medical, Inc., Santa Rosa, CA, USA) for cerebral pro-
tection. For TAVI in aortic position 13 Corevalve/Evolut R, 2 Portico
and 1 Sapien valve were used. For bioprostheses in the mitral position
Sapien/Sapien 3 prostheses were exclusively implanted. Access routes
were transfemoral (n¼14), transapical (n¼3), transaxillary (n¼2) and
transseptal (n¼2). Mean patient age was 75  1s years; mean logistic
EuroSCORE was 35.7%. Clinical follow-up by a cardiologist was ob-
tained 3 days after the intervention and at discharge (mean 9 days). In
cases of suspected stroke, a neurologist were consulted. Histological
analyses were performed in 7 patients by the CVPath Institute in
Gaithersburg, MD (additional 3 analyses are in progress).
RESULTS TAVR device success rate was 77% due to high mean gradi-
ents for implantations in the aortic position. Stroke rate up to discharge
was 0%. TAVI device success rate was 77% due to high mean gradients
